Literature DB >> 24124965

The artificial pancreas: is it important to understand how the β cell controls blood glucose?

Garry M Steil1, Gerold M Grodsky.   

Abstract

It has been more than 7 years since the first fully automated closed-loop insulin delivery system that linked subcutaneous insulin delivery and glucose sensing was published. Since the initial report, the physiologic insulin delivery (PID) algorithm used to emulate the β cell has been modified from the original proportional-integral-derivative terms needed to fit the β cell's biphasic response to a hyperglycemic clamp to include terms emulating cephalic phase insulin release and the effect of insulin per se to inhibit insulin secretion. In this article, we compare the closed-loop glucose profiles obtained as each new term has been added, reassess the ability of the revised PID model to describe the β cells' insulin response to a hyperglycemic clamp, and look for the first time at its ability to describe the response to a hypoglycemic clamp. We also consider changes that might be added to the model based on perfused pancreas data. We conclude that the changes introduced in the PID model have systematically improved the closed-loop meal response. We note that the changes made do not adversely affect the ability of the model to fit hyperglycemic clamp data but are necessary to fit the response to a hypoglycemic clamp. Finally, we note a number of β cell characteristics observed in the perfused pancreas have not been included in the model. We suggest that continuing the effort to understand and incorporate aspects of how the β cell achieves glucose control can provide valuable insights into how improvements in future artificial pancreas algorithms might be achieved.
© 2013 Diabetes Technology Society.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24124965      PMCID: PMC3876382          DOI: 10.1177/193229681300700528

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


  69 in total

1.  A bihormonal closed-loop artificial pancreas for type 1 diabetes.

Authors:  Firas H El-Khatib; Steven J Russell; David M Nathan; Robert G Sutherlin; Edward R Damiano
Journal:  Sci Transl Med       Date:  2010-04-14       Impact factor: 17.956

2.  Closed-loop artificial pancreas using subcutaneous glucose sensing and insulin delivery and a model predictive control algorithm: the Virginia experience.

Authors:  William L Clarke; Stacey Anderson; Marc Breton; Stephen Patek; Laurissa Kashmer; Boris Kovatchev
Journal:  J Diabetes Sci Technol       Date:  2009-09-01

3.  Evidence that glucose "marks" beta cells resulting in preferential release of newly synthesized insulin.

Authors:  G Gold; M L Gishizky; G M Grodsky
Journal:  Science       Date:  1982-10-01       Impact factor: 47.728

4.  Heterogeneity and compartmental properties of insulin storage and secretion in rat islets.

Authors:  G Gold; H D Landahl; M L Gishizky; G M Grodsky
Journal:  J Clin Invest       Date:  1982-03       Impact factor: 14.808

5.  Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose.

Authors:  R N Bergman; L S Phillips; C Cobelli
Journal:  J Clin Invest       Date:  1981-12       Impact factor: 14.808

6.  The effect of insulin feedback on closed loop glucose control.

Authors:  Garry M Steil; Cesar C Palerm; Natalie Kurtz; Gayane Voskanyan; Anirban Roy; Sachiko Paz; Fouad R Kandeel
Journal:  J Clin Endocrinol Metab       Date:  2011-03-02       Impact factor: 5.958

Review 7.  How neural mediation of anticipatory and compensatory insulin release helps us tolerate food.

Authors:  Karen L Teff
Journal:  Physiol Behav       Date:  2011-01-20

8.  Feedback inhibition of insulin secretion by insulin: relation to the hyperinsulinemia of obesity.

Authors:  D Elahi; M Nagulesparan; R J Hershcopf; D C Muller; J D Tobin; P M Blix; A H Rubenstein; R H Unger; R Andres
Journal:  N Engl J Med       Date:  1982-05-20       Impact factor: 91.245

9.  Time and dose dependencies for priming effect of glucose on insulin secretion.

Authors:  V Grill
Journal:  Am J Physiol       Date:  1981-01

10.  Closed-loop insulin delivery using a subcutaneous glucose sensor and intraperitoneal insulin delivery: feasibility study testing a new model for the artificial pancreas.

Authors:  Eric Renard; Jerome Place; Martin Cantwell; Hugues Chevassus; Cesar C Palerm
Journal:  Diabetes Care       Date:  2009-10-21       Impact factor: 19.112

View more
  5 in total

1.  Algorithms for a closed-loop artificial pancreas: the case for proportional-integral-derivative control.

Authors:  Garry M Steil
Journal:  J Diabetes Sci Technol       Date:  2013-11-01

2.  Slow potentials encode intercellular coupling and insulin demand in pancreatic beta cells.

Authors:  Fanny Lebreton; Antoine Pirog; Isma Belouah; Domenico Bosco; Thierry Berney; Paolo Meda; Yannick Bornat; Bogdan Catargi; Sylvie Renaud; Matthieu Raoux; Jochen Lang
Journal:  Diabetologia       Date:  2015-03-19       Impact factor: 10.122

3.  Tight glycemic control after pediatric cardiac surgery in high-risk patient populations: a secondary analysis of the safe pediatric euglycemia after cardiac surgery trial.

Authors:  Michael S D Agus; Lisa A Asaro; Garry M Steil; Jamin L Alexander; Melanie Silverman; David Wypij; Michael G Gaies
Journal:  Circulation       Date:  2014-03-26       Impact factor: 29.690

4.  The artificial pancreas: evaluating risk of hypoglycaemia following errors that can be expected with prolonged at-home use.

Authors:  H Wolpert; M Kavanagh; A Atakov-Castillo; G M Steil
Journal:  Diabet Med       Date:  2015-07-04       Impact factor: 4.359

5.  Feasibility study of a bio-inspired artificial pancreas in adults with type 1 diabetes.

Authors:  Monika Reddy; Pau Herrero; Mohamed El Sharkawy; Peter Pesl; Narvada Jugnee; Hazel Thomson; Darrell Pavitt; Christofer Toumazou; Desmond Johnston; Pantelis Georgiou; Nick Oliver
Journal:  Diabetes Technol Ther       Date:  2014-05-06       Impact factor: 6.118

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.